Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
10 studies found for:    Multifocal Motor Neuropathy

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Enrolling by invitation Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.
Condition: Multifocal Motor Neuropathy
Intervention: Drug: NPB-01
2 Completed Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy
Condition: Multifocal Motor Neuropathy
Interventions: Drug: Subcutaneous immunoglobulin;   Drug: Intravenous immunoglobulin
3 Completed
Has Results 		Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
Condition: Multifocal Motor Neuropathy
Interventions: Biological: Immune Globulin Intravenous (human), 10%;   Biological: 0.25% human albumin solution (Placebo)
4 Completed
Has Results 		A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)
Condition: Multifocal Motor Neuropathy (MMN)
Intervention: Biological: Vivaglobin
5 Enrolling by invitation MRI and Ultrasound Imaging in Diagnosing and Monitoring CIDP and MMN
Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy;   Multifocal Motor Neuropathy
Intervention:
6 Enrolling by invitation Effect of Resistance and Aerobic Exercise in CIDP or MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy
Interventions: Other: Resistance training;   Other: Aerobic training
7 Recruiting Immunoglobulin Dosage and Administration Form in CIDP and MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy;   Hemolytic Anemia
Intervention: Drug: Immunoglobulins
8 Recruiting LIME Study (LFB IVIG MMN Efficacy Study)
Condition: Motor Neuron Disease
Interventions: Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);   Drug: Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
9 Not yet recruiting sCD163 in CIDP and MMN
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Procedure: lumbar puncture for spinal fluid and blod sample
10 Active, not recruiting Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
Conditions: Guillain-Barre Syndrome;   CIDP;   Multifocal Motor Neuropathy
Intervention:
To Top

† Indicates status has not been verified in more than two years